Patents by Inventor Yonghong Wu

Yonghong Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11945807
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 2, 2024
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
  • Patent number: 9630999
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: April 25, 2017
    Assignees: Suzhou Sciscape Biomedicine Science & Technology Co. Ltd., Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China
    Inventors: Chenggang Zhang, Junhuai Li, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li
  • Publication number: 20160060305
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Application
    Filed: November 13, 2015
    Publication date: March 3, 2016
    Applicants: SUZHOU SCISCAPE BIOMEDICINE SCIENCE & TECHNOLOGY CO. LTD., INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIB
    Inventors: Chenggang ZHANG, Junhuai LI, Yang XU, Yonghong WU, Weiguang LI, Yanchun ZHANG, Yan GAO, Zhihui LI
  • Patent number: 9259453
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: February 16, 2016
    Assignees: Suzhou Sciscape Biomedicine Science & Technology Co. Ltd., Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China
    Inventors: Chenggang Zhang, Junhuai Li, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li
  • Publication number: 20140248348
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Application
    Filed: January 19, 2012
    Publication date: September 4, 2014
    Applicants: SUZHOU SCISCAPE BIOMEDICINE SCIENCE & TECHNOLOGY CO. LTD., PEOPLE'S LIBERATION ARMY OF CHINA
    Inventors: Chenggang Zhang, Junhuai Li, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li
  • Patent number: 7889856
    Abstract: Disclosed are systems and methods for providing ring back tones in a communication network. At first, a ring back tone device for storing and playing the ring back tone customized by a subscriber is established in the communication network. Whether a subscriber is a ring back tone service register subscriber is judged with a certain triggering mode, such as intelligent network triggering, signaling interception triggering, call forwarding triggering or switching device triggering. If it is judged the subscriber is a ring back tone service registered subscriber, a connection between the originating switching device and the terminating switching device and a connection between a switching device and the ring back tone device are established. When the called terminal is idle, the ring back tone device provides a piece of customized ring back tone to the calling subscriber for replacing traditional ring back tone.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: February 15, 2011
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Bin Wang, Yihua Cheng, Xiaoqing Hu, Xiaojun Mo, Jihong Dong, Qian Yu, Xuanming Lu, Xiaodong Zhao, Yongfeng Cai, Junrong Xu, Guodao Yang, Youjun Chen, Zujian Li, Guofan Tong, Shichang Xiao, Yi Zhang, Jiaqing Liu, Yonghong Wu, Shiqian Li
  • Publication number: 20060153355
    Abstract: Disclosed are systems and methods for providing ring back tones in a communication network. At first, a ring back tone device for storing and playing the ring back tone customized by a subscriber is established in the communication network. Whether a subscriber is a ring back tone service register subscriber is judged with a certain triggering mode, such as intelligent network triggering, signaling interception triggering, call forwarding triggering or switching device triggering. If it is judged the subscriber is a ring back tone service registered subscriber, a connection between the originating switching device and the terminating switching device and a connection between a switching device and the ring back tone device are established. When the called terminal is idle, the ring back tone device provides a piece of customized ring back tone to the calling subscriber for replacing traditional ring back tone.
    Type: Application
    Filed: November 15, 2005
    Publication date: July 13, 2006
    Applicant: Huawei Technologies Co., Ltd.
    Inventors: Bin Wang, Yihua Cheng, Xiaoqing Hu, Xiaojun Mo, Jihong Dong, Qian Yu, Xuanming Lu, Xiaodong Zhao, Yongfeng Cai, Junrong Xu, Guodao Yang, Youjun Chen, Zujian Li, Guofan Tong, Shichang Xiao, Yi Zhang, Jiaqing Liu, Yonghong Wu, Shiqian Li